This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bartel, F. Articles by Taubert, H. Search for Related Content PubMed PubMed Citation Articles by Bartel, F. Articles by Taubert, H. Related Collections Cellular Pathobiology Cellular Pathobiology: Cancer Genes and Genomics

---

Subject Review

MDM2 and Its Splice Variant Messenger RNAs: Expression in Tumors and Down-Regulation Using Antisense Oligonucleotides¹

¹ Institute of Pathology, Faculty of Medicine, University of Halle-Wittenberg, Halle/Saale, Germany; ² Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis TN; and ³ Surgical Clinic I, Faculty of Medicine, University of Ulm, Ulm, Germany

Requests for reprints: Frank Bartel, Institute of Pathology, Faculty of Medicine, University of Halle-Wittenberg, D-06097 Halle/Saale, Germany. Phone: 49-345-557-4272; Fax: 49-345-557-1295. E-mail: frank.bartel{at}medizin.uni-halle.de

Alternative splicing has an important role in expanding protein diversity. An example of a gene with more than one transcript is the MDM2 oncogene. To date, more than 40 different splice variants have been isolated from both tumor and normal tissues. Here, we review what is known about the alteration of MDM2 mRNA expression, focusing on alternative splicing and potential functions of different MDM2 isoforms. We also discuss the progress that has been made in the development of antisense oligonucleotides targeted to MDM2 for use as a potential cancer therapy.

This article has been cited by other articles:

				A. Forslund, Z. Zeng, L.-X. Qin, S. Rosenberg, M. Ndubuisi, H. Pincas, W. Gerald, D. A. Notterman, F. Barany, and P. B. Paty MDM2 Gene Amplification Is Correlated to Tumor Progression but not to the Presence of SNP309 or TP53 Mutational Status in Primary Colorectal Cancers Mol. Cancer Res., February 1, 2008; 6(2): 205 - 211. [Abstract] [Full Text] [PDF]

				B. Wawrzynow, A. Zylicz, M. Wallace, T. Hupp, and M. Zylicz MDM2 Chaperones the p53 Tumor Suppressor J. Biol. Chem., November 9, 2007; 282(45): 32603 - 32612. [Abstract] [Full Text] [PDF]

				C. Kannemeier, R. Liao, and P. Sun The RING Finger Domain of MDM2 Is Essential for MDM2-mediated TGF-beta Resistance Mol. Biol. Cell, June 1, 2007; 18(6): 2367 - 2377. [Abstract] [Full Text] [PDF]

				J.-C. W. Marine, M. A. Dyer, and A. G. Jochemsen MDMX: from bench to bedside J. Cell Sci., February 1, 2007; 120(3): 371 - 378. [Abstract] [Full Text] [PDF]

				H. K. Koblish, S. Zhao, C. F. Franks, R. R. Donatelli, R. M. Tominovich, L. V. LaFrance, K. A. Leonard, J. M. Gushue, D. J. Parks, R. R. Calvo, et al. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo Mol. Cancer Ther., January 1, 2006; 5(1): 160 - 169. [Abstract] [Full Text] [PDF]

				B. Diesel, J. Radermacher, M. Bureik, R. Bernhardt, M. Seifert, J. Reichrath, U. Fischer, and E. Meese Vitamin D3 Metabolism in Human Glioblastoma Multiforme: Functionality of CYP27B1 Splice Variants, Metabolism of Calcidiol, and Effect of Calcitriol Clin. Cancer Res., August 1, 2005; 11(15): 5370 - 5380. [Abstract] [Full Text] [PDF]